The Indian Competition Authority approves acquisition of pharmaceutical company's business by foreign venture capital firm (FIL Capital Investments (Mauritius) II / Cipla Health)

Sharma, Man Mohan

Previous article The EU Commission clears acquisition of a fourth largest global manufacturer of generic medicines by the largest global competitor, subject to complex remedies and monitoring, including addressing concerns about vertical relationships between parties for the first time in a generics merger (Teva / Allergan Generics) Next article The EU Commission increases merger control enforcement in the pharmaceutical sector

15 Jan 2016

The Indian Competition Authority approves acquisition of pharmaceutical company’s business by foreign venture capital firm (FIL Capital Investments (Mauritius) II / Cipla Health)

KEYWORDS

Reference

Indian Competition Authority, FIL Capital Investments (Mauritius) II / Cipla Health, Combination Registration No. C-2015/12/360, 15 January 2016

CCI approves proposed combination notice filed by FIL Capital Investments (Mauritius) II Limited* The CCI, by its order dated January 15, 2016 has approved the proposed combination relating to the acquisition of 26.11% shareholding of the paid-up equity share capital of the Cipla

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

PDF Version

Author

Man Mohan Sharma
Vaish Associates Advocates (New Delhi)

India 263 contributions 41126 visits

Quotation

Man Mohan Sharma, The Indian Competition Authority approves acquisition of pharmaceutical company’s business by foreign venture capital firm (FIL Capital Investments (Mauritius) II / Cipla Health), 15 January 2016, e-Competitions Pharma & Mergers, Art. N° 87743

Visites 157